Market Size of Germany Diabetes Drugs Industry
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 4.06 Billion |
| Market Size (2029) | USD 4.81 Billion |
| CAGR (2024 - 2029) | 3.47 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Germany Diabetes Drugs Market Analysis
The Germany Diabetes Drugs Market size is estimated at USD 4.06 billion in 2024, and is expected to reach USD 4.81 billion by 2029, growing at a CAGR of 3.47% during the forecast period (2024-2029).
The rate of newly diagnosed Type 1 and Type 2 diabetes cases is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of diabetic care drugs.
Diabetes is a significant health problem and one of the tremendous challenges for healthcare systems all over Germany. The disease's growing incidence, prevalence, and progressive nature encouraged the development of new drugs to provide additional treatment options for diabetic patients. The roll-out of many new products, increasing international research collaborations in technology advancement, and increasing awareness about diabetes among the people are some of the market opportunities for the players in the Germany diabetes drugs market.
Stringent government policies and favorable regulations by WHO in Germany are encouraging companies to develop innovative products. Penetration of these products in the German market supports local organizations in their clinical research trials and ensures ease of management, facilitating the discovery process.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Germany Diabetes Drugs Industry Segmentation
Diabetes Drugs are used to manage diabetes mellitus by lowering the glucose level in the blood. The Germany Diabetes Drugs Market is segmented into drugs. The report offers the value (in USD) and volume (in units) for the above segments.
| Insulins | |||||||
| |||||||
| |||||||
| |||||||
|
| Oral Anti-diabetic drugs | ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
|
| Non-Insulin Injectable drugs | |||||||
| |||||||
|
| Combination drugs | |||||
| |||||
|
Germany Diabetes Drugs Market Size Summary
The Germany Diabetes Drugs Market is poised for growth, driven by the increasing incidence of Type 1 and Type 2 diabetes, largely attributed to factors such as obesity, unhealthy diets, and physical inactivity. This rising prevalence underscores the demand for diabetes care drugs, supported by healthcare expenditure and the development of new treatment options. The market is characterized by opportunities arising from the introduction of innovative products, international research collaborations, and heightened awareness of diabetes. Government policies and favorable regulations by the World Health Organization are further encouraging the development of novel drugs, facilitating clinical research trials and easing the management of diabetes care.
The market landscape is dominated by oral anti-diabetic drugs, which hold a significant share due to their efficacy, safety, and cost-effectiveness, making them a preferred choice for managing Type 2 diabetes. The Sodium-Glucose Cotransport -2 (SGLT-2) inhibitor segment is expected to lead the market, offering benefits such as cardiovascular risk management and weight loss, with a low risk of hypoglycemia. The fragmented market features major players like Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca, who are actively engaging in strategy-based mergers and acquisitions to expand their market presence. The integration of health and treatment data in diabetes management further highlights the evolving nature of the market, with both patients and providers leveraging data for personalized care.
Germany Diabetes Drugs Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.3 Market Restraints
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products and Services
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 Insulins
-
2.1.1 Basal or Long Acting Insulins
-
2.1.1.1 Lantus (Insulin Glargine)
-
2.1.1.2 Levemir (Insulin Detemir)
-
2.1.1.3 Toujeo (Insulin Glargine)
-
2.1.1.4 Tresiba (Insulin Degludec)
-
2.1.1.5 Basaglar (Insulin Glargine)
-
-
2.1.2 Bolus or Fast Acting Insulins
-
2.1.2.1 NovoRapid/Novolog (Insulin Aspart)
-
2.1.2.2 Humalog (Insulin Lispro)
-
2.1.2.3 Apidra (Insulin Glulisine)
-
-
2.1.3 Traditional Human Insulins
-
2.1.3.1 Novolin/Actrapid/Insulatard
-
2.1.3.2 Humulin
-
2.1.3.3 Insuman
-
-
2.1.4 Biosimilar Insulins
-
2.1.4.1 Insulin Glargine Biosimilars
-
2.1.4.2 Human Insulin Biosimilars
-
-
-
2.2 Oral Anti-diabetic drugs
-
2.2.1 Biguanides
-
2.2.1.1 Metformin
-
-
2.2.2 Alpha-Glucosidase Inhibitors
-
2.2.2.1 Alpha-Glucosidase Inhibitors
-
-
2.2.3 Dopamine D2 receptor agonist
-
2.2.3.1 Bromocriptin
-
-
2.2.4 SGLT-2 inhibitors
-
2.2.4.1 Invokana (Canagliflozin)
-
2.2.4.2 Jardiance (Empagliflozin)
-
2.2.4.3 Farxiga/Forxiga (Dapagliflozin)
-
2.2.4.4 Suglat (Ipragliflozin)
-
-
2.2.5 DPP-4 inhibitors
-
2.2.5.1 Onglyza (Saxagliptin)
-
2.2.5.2 Tradjenta (Linagliptin)
-
2.2.5.3 Vipidia/Nesina(Alogliptin)
-
2.2.5.4 Galvus (Vildagliptin)
-
-
2.2.6 Sulfonylureas
-
2.2.6.1 Sulfonylureas
-
-
2.2.7 Meglitinides
-
2.2.7.1 Meglitinides
-
-
-
2.3 Non-Insulin Injectable drugs
-
2.3.1 GLP-1 receptor agonists
-
2.3.1.1 Victoza (Liraglutide)
-
2.3.1.2 Byetta (Exenatide)
-
2.3.1.3 Bydureon (Exenatide)
-
2.3.1.4 Trulicity (Dulaglutide)
-
2.3.1.5 Lyxumia (Lixisenatide)
-
-
2.3.2 Amylin Analogue
-
2.3.2.1 Symlin (Pramlintide)
-
-
-
2.4 Combination drugs
-
2.4.1 Insulin combinations
-
2.4.1.1 NovoMix (Biphasic Insulin Aspart)
-
2.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
-
2.4.1.3 Xultophy (Insulin Degludec and Liraglutide)
-
-
2.4.2 Oral Combinations
-
2.4.2.1 Janumet (Sitagliptin and Metformin)
-
-
-
Germany Diabetes Drugs Market Size FAQs
How big is the Germany Diabetes Drugs Market?
The Germany Diabetes Drugs Market size is expected to reach USD 4.06 billion in 2024 and grow at a CAGR of 3.47% to reach USD 4.81 billion by 2029.
What is the current Germany Diabetes Drugs Market size?
In 2024, the Germany Diabetes Drugs Market size is expected to reach USD 4.06 billion.
